Mohammad Motiur Rahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammad Motiur Rahman has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Marufa Mustari
Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
4 shared publications - Mohammad Abdul Hannan
Department of Endocrinology, North East Medical College & Hospital, Sylhet, 3100, Bangladesh
4 shared publications - Shahjada Selim
Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
4 shared publications - Abu Jar Gaffar
Department of Pathology, Naogaon Medical College, Naogaon, Bangladesh
3 shared publications - Abul Bashar Mohammad Kamrul Hasan
Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh
3 shared publications - Afsar Ahammed
Associate Professor, Department of Endocrinology, Dhaka Medical College, Dhaka, Bangladesh
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Ordient Publishers in TAJ: Journal of Teachers Association
- Vol. 39 (2) , 67-77
A Clinicopathological Study of Gestational Trophoblastic Disease
Background: Gestational trophoblastic disease (GTD) comprises a heterogeneous spectrum of placental trophoblastic proliferations with substantial diagnostic and prognostic implications in reproductive-aged women. Objective: To delineate the clinicopathological profile of GTD in a tertiary care population and identify demographic, clinical, and histological determinants of disease presentation. Methods: An observational cross-sectional investigation was undertaken in the Department of Obstetrics and Gynaecology, Rajshahi Medical College Hospital, from September 2013 to February 2014. Thirty consecutive histopathologically confirmed cases of GTD were evaluated. Demographic parameters, clinical presentation, haematological indices, serum β-human chorionic gonadotropin (β-hCG) titres, and histopathological grading were systematically recorded. Statistical analyses were executed using SPSS version 26.0. Results: Histopathology demonstrated hydatidiform mole in 23 cases (76.7%), invasive mole in 1 (3.3%), choriocarcinoma in 2 (6.7%), placental site trophoblastic tumour (PSTT) in 1 (3.3%), and placental site trophoblastic reaction (PSTR) in 3 (10.0%), constituting 23.3% of gynaecological tumours and 0.96% (1:103) of total deliveries. The modal age was 21–30 years (46.7%; mean 27.4 ± 6.8 years; p = 0.003). Blood group A predominated (43.3%). Muslim ethnicity accounted for 73.3% of cases. Bleeding per vagina (100%), amenorrhoea (90%), and abdominal pain (60%) were cardinal symptoms. Mean serum β-hCG was 186,420 ± 72,350 mIU/mL, with choriocarcinoma showing markedly elevated levels (580,200 ± 75,400 mIU/mL; ANOVA p < 0.001). Grade-I moles (n = 17) behaved benignly, whereas Grade-II (n = 5) and Grade-III (n = 1) lesions showed malignant potential. Uterine enlargement exceeded gestational age in 70.0% of complete moles (χ² = 14.82, p = 0.011). Mean haemoglobin was 8.9 ± 1.4 g/dL. Conclusion: GTD represents a clinicopathologically diverse entity with distinct demographic predilections; early histopathological characterisation and β-hCG surveillance are pivotal for reducing malignant progression and mortality.
- 1 June 2026
- Published by Ordient Publishers in TAJ: Journal of Teachers Association
- Vol. 39 (2) , 67-77
Open AccessA Clinicopathological Study of Gestational Trophoblastic Disease
Background: Gestational trophoblastic disease (GTD) comprises a heterogeneous spectrum of placental trophoblastic proliferations with substantial diagnostic and prognostic implications in reproductive-aged women. Objective: To delineate the clinicopathological profile of GTD in a tertiary care population and identify demographic, clinical, and histological determinants of disease presentation. Methods: An observational cross-sectional investigation was undertaken in the Department of Obstetrics and Gynaecology, Rajshahi Medical College Hospital, from September 2013 to February 2014. Thirty consecutive histopathologically confirmed cases of GTD were evaluated. Demographic parameters, clinical presentation, haematological indices, serum β-human chorionic gonadotropin (β-hCG) titres, and histopathological grading were systematically recorded. Statistical analyses were executed using SPSS version 26.0. Results: Histopathology demonstrated hydatidiform mole in 23 cases (76.7%), invasive mole in 1 (3.3%), choriocarcinoma in 2 (6.7%), placental site trophoblastic tumour (PSTT) in 1 (3.3%), and placental site trophoblastic reaction (PSTR) in 3 (10.0%), constituting 23.3% of gynaecological tumours and 0.96% (1:103) of total deliveries. The modal age was 21–30 years (46.7%; mean 27.4 ± 6.8 years; p = 0.003). Blood group A predominated (43.3%). Muslim ethnicity accounted for 73.3% of cases. Bleeding per vagina (100%), amenorrhoea (90%), and abdominal pain (60%) were cardinal symptoms. Mean serum β-hCG was 186,420 ± 72,350 mIU/mL, with choriocarcinoma showing markedly elevated levels (580,200 ± 75,400 mIU/mL; ANOVA p < 0.001). Grade-I moles (n = 17) behaved benignly, whereas Grade-II (n = 5) and Grade-III (n = 1) lesions showed malignant potential. Uterine enlargement exceeded gestational age in 70.0% of complete moles (χ² = 14.82, p = 0.011). Mean haemoglobin was 8.9 ± 1.4 g/dL. Conclusion: GTD represents a clinicopathologically diverse entity with distinct demographic predilections; early histopathological characterisation and β-hCG surveillance are pivotal for reducing malignant progression and mortality.
- Open Access
- 1 June 2026
- Published by Ordient Publishers in TAJ: Journal of Teachers Association
- Vol. 39 (2) , 67-77
A Clinicopathological Study of Gestational Trophoblastic Disease
Background: Gestational trophoblastic disease (GTD) comprises a heterogeneous spectrum of placental trophoblastic proliferations with substantial diagnostic and prognostic implications in reproductive-aged women. Objective: To delineate the clinicopathological profile of GTD in a tertiary care population and identify demographic, clinical, and histological determinants of disease presentation. Methods: An observational cross-sectional investigation was undertaken in the Department of Obstetrics and Gynaecology, Rajshahi Medical College Hospital, from September 2013 to February 2014. Thirty consecutive histopathologically confirmed cases of GTD were evaluated. Demographic parameters, clinical presentation, haematological indices, serum β-human chorionic gonadotropin (β-hCG) titres, and histopathological grading were systematically recorded. Statistical analyses were executed using SPSS version 26.0. Results: Histopathology demonstrated hydatidiform mole in 23 cases (76.7%), invasive mole in 1 (3.3%), choriocarcinoma in 2 (6.7%), placental site trophoblastic tumour (PSTT) in 1 (3.3%), and placental site trophoblastic reaction (PSTR) in 3 (10.0%), constituting 23.3% of gynaecological tumours and 0.96% (1:103) of total deliveries. The modal age was 21–30 years (46.7%; mean 27.4 ± 6.8 years; p = 0.003). Blood group A predominated (43.3%). Muslim ethnicity accounted for 73.3% of cases. Bleeding per vagina (100%), amenorrhoea (90%), and abdominal pain (60%) were cardinal symptoms. Mean serum β-hCG was 186,420 ± 72,350 mIU/mL, with choriocarcinoma showing markedly elevated levels (580,200 ± 75,400 mIU/mL; ANOVA p < 0.001). Grade-I moles (n = 17) behaved benignly, whereas Grade-II (n = 5) and Grade-III (n = 1) lesions showed malignant potential. Uterine enlargement exceeded gestational age in 70.0% of complete moles (χ² = 14.82, p = 0.011). Mean haemoglobin was 8.9 ± 1.4 g/dL. Conclusion: GTD represents a clinicopathologically diverse entity with distinct demographic predilections; early histopathological characterisation and β-hCG surveillance are pivotal for reducing malignant progression and mortality.
- 1 June 2026
- Published by Ordient Publishers in TAJ: Journal of Teachers Association
- Vol. 39 (2) , 67-77
Open AccessA Clinicopathological Study of Gestational Trophoblastic Disease
Background: Gestational trophoblastic disease (GTD) comprises a heterogeneous spectrum of placental trophoblastic proliferations with substantial diagnostic and prognostic implications in reproductive-aged women. Objective: To delineate the clinicopathological profile of GTD in a tertiary care population and identify demographic, clinical, and histological determinants of disease presentation. Methods: An observational cross-sectional investigation was undertaken in the Department of Obstetrics and Gynaecology, Rajshahi Medical College Hospital, from September 2013 to February 2014. Thirty consecutive histopathologically confirmed cases of GTD were evaluated. Demographic parameters, clinical presentation, haematological indices, serum β-human chorionic gonadotropin (β-hCG) titres, and histopathological grading were systematically recorded. Statistical analyses were executed using SPSS version 26.0. Results: Histopathology demonstrated hydatidiform mole in 23 cases (76.7%), invasive mole in 1 (3.3%), choriocarcinoma in 2 (6.7%), placental site trophoblastic tumour (PSTT) in 1 (3.3%), and placental site trophoblastic reaction (PSTR) in 3 (10.0%), constituting 23.3% of gynaecological tumours and 0.96% (1:103) of total deliveries. The modal age was 21–30 years (46.7%; mean 27.4 ± 6.8 years; p = 0.003). Blood group A predominated (43.3%). Muslim ethnicity accounted for 73.3% of cases. Bleeding per vagina (100%), amenorrhoea (90%), and abdominal pain (60%) were cardinal symptoms. Mean serum β-hCG was 186,420 ± 72,350 mIU/mL, with choriocarcinoma showing markedly elevated levels (580,200 ± 75,400 mIU/mL; ANOVA p < 0.001). Grade-I moles (n = 17) behaved benignly, whereas Grade-II (n = 5) and Grade-III (n = 1) lesions showed malignant potential. Uterine enlargement exceeded gestational age in 70.0% of complete moles (χ² = 14.82, p = 0.011). Mean haemoglobin was 8.9 ± 1.4 g/dL. Conclusion: GTD represents a clinicopathologically diverse entity with distinct demographic predilections; early histopathological characterisation and β-hCG surveillance are pivotal for reducing malignant progression and mortality.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-16
Real-World Effectiveness and Safety of Imeglimin in Type 2 Diabetes: Prospective Multi-Center Study in Bangladesh
Background: This study assessed the real-world effectiveness and safety of imeglimin among Bangladeshi patients with type 2 diabetes mellitus (T2DM). Methods: This prospective, multi-center observational study was conducted across 15 specialized diabetes care centers in Bangladesh from January 2024 to December 2024. Adults with uncontrolled T2DM (HbA1c > 7%) prescribed imeglimin (500– 2000 mg daily) either as monotherapy or combination therapy were enrolled. A total of 898 subjects were assessed at baseline, 3 months, and 6 months. Primary outcomes were changes in HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPPG). Secondary outcomes included body mass index (BMI), blood pressure, lipids, and safety parameters. Results: The mean age was 46.2 ± 13.1 (SD) years, with 67% being female. Baseline HbA1c decreased from 9.2± 1.4% to 7.1± 1.0% at 6 months (mean change: − 2.1%, p< 0.001). FPG reduced from 9.37± 2.53 to 7.28± 4.63 mmol/L (p< 0.001) and PPPG from 14.36± 3.29 to 8.95± 1.76 mmol/L (p< 0.001). BMI decreased from 28.1± 4.2 to 25.6± 3.6 kg/m2 (p< 0.001). Significant improvements occurred in blood pressure, lipids, and renal parameters. Adverse events were mild; 3.6% reported ≥ 1 event (gastrointestinal 2.4%, dehydration 1.3%). No serious adverse events occurred. Conclusion: Imeglimin demonstrated substantial glycemic improvements and favorable safety in real-world Bangladeshi patients with poor glycemic control.
- 1 February 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-16
Open AccessReal-World Effectiveness and Safety of Imeglimin in Type 2 Diabetes: Prospective Multi-Center Study in Bangladesh
Background: This study assessed the real-world effectiveness and safety of imeglimin among Bangladeshi patients with type 2 diabetes mellitus (T2DM). Methods: This prospective, multi-center observational study was conducted across 15 specialized diabetes care centers in Bangladesh from January 2024 to December 2024. Adults with uncontrolled T2DM (HbA1c > 7%) prescribed imeglimin (500– 2000 mg daily) either as monotherapy or combination therapy were enrolled. A total of 898 subjects were assessed at baseline, 3 months, and 6 months. Primary outcomes were changes in HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPPG). Secondary outcomes included body mass index (BMI), blood pressure, lipids, and safety parameters. Results: The mean age was 46.2 ± 13.1 (SD) years, with 67% being female. Baseline HbA1c decreased from 9.2± 1.4% to 7.1± 1.0% at 6 months (mean change: − 2.1%, p< 0.001). FPG reduced from 9.37± 2.53 to 7.28± 4.63 mmol/L (p< 0.001) and PPPG from 14.36± 3.29 to 8.95± 1.76 mmol/L (p< 0.001). BMI decreased from 28.1± 4.2 to 25.6± 3.6 kg/m2 (p< 0.001). Significant improvements occurred in blood pressure, lipids, and renal parameters. Adverse events were mild; 3.6% reported ≥ 1 event (gastrointestinal 2.4%, dehydration 1.3%). No serious adverse events occurred. Conclusion: Imeglimin demonstrated substantial glycemic improvements and favorable safety in real-world Bangladeshi patients with poor glycemic control.
- Open Access
- 1 December 2025
- Published by Ordient Publishers in TAJ: Journal of Teachers Association
- Vol. 38 (4) , 220-224
Status of Glucose Intolerance in Overweight and Obese Polycystic Ovary Syndrome Women
PCOS is a common condition in female due to hormonal imbalance. Both normal-weight and overweight women can develop PCOS. But there is a close relationship between body mass index (BMI) and polycystic ovarian syndrome (PCOS) and BMI can influence the severity of PCOS symptoms. It was a cross-sectional type of descriptive study on 550 women with PCOS attending in the Department of Medicine, Rajshahi Medical College Hospital, Rajshahi over a period of one and half year from July 2020 to June 2023. Data were collected by a semi-structured questionnaire and sampling technique was purposive. A p-value of less than 0.05 was considered statistically significant for all tests. Mean age, BMI and waist circumference of the PCOS women were 22.18±5.40 years, 28.02±6.07 kg/m2 and 93.02±15.77 cm, respectively. Mean fasting and 2 hours after 75gm glucose were 5.28±1.09 mmol/L and 7.23±2.07 mmol/L, respectively. Overweight and obese women had significantly higher levels of impaired and diabetic women compared to the underweight and normal weight groups in terms of fasting plasma glucose and 2-hour after 75gm glucose levels (p=0.01 and p < 0.001, respectively). Overweight and obesity are associated with polycystic ovary syndrome (PCOS). They should be controlled by dieting and changing lifestyle to improve symptoms in PCOS.
- 1 December 2025
- Published by Ordient Publishers in TAJ: Journal of Teachers Association
- Vol. 38 (4) , 220-224
Open AccessStatus of Glucose Intolerance in Overweight and Obese Polycystic Ovary Syndrome Women
PCOS is a common condition in female due to hormonal imbalance. Both normal-weight and overweight women can develop PCOS. But there is a close relationship between body mass index (BMI) and polycystic ovarian syndrome (PCOS) and BMI can influence the severity of PCOS symptoms. It was a cross-sectional type of descriptive study on 550 women with PCOS attending in the Department of Medicine, Rajshahi Medical College Hospital, Rajshahi over a period of one and half year from July 2020 to June 2023. Data were collected by a semi-structured questionnaire and sampling technique was purposive. A p-value of less than 0.05 was considered statistically significant for all tests. Mean age, BMI and waist circumference of the PCOS women were 22.18±5.40 years, 28.02±6.07 kg/m2 and 93.02±15.77 cm, respectively. Mean fasting and 2 hours after 75gm glucose were 5.28±1.09 mmol/L and 7.23±2.07 mmol/L, respectively. Overweight and obese women had significantly higher levels of impaired and diabetic women compared to the underweight and normal weight groups in terms of fasting plasma glucose and 2-hour after 75gm glucose levels (p=0.01 and p < 0.001, respectively). Overweight and obesity are associated with polycystic ovary syndrome (PCOS). They should be controlled by dieting and changing lifestyle to improve symptoms in PCOS.
- Open Access
- 6 April 2025
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 25, 200399
Cardiovascular risk in newly diagnosed patients with type 2 diabetes mellitus: a nationwide, facility-based, cross-sectional study in Bangladesh
- 6 April 2025
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 25, 200399
Open AccessCardiovascular risk in newly diagnosed patients with type 2 diabetes mellitus: a nationwide, facility-based, cross-sectional study in Bangladesh
- Open Access
- 5 December 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-9
Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study
Background: Achievement of lipid targets is crucial in patients with type 2 diabetes mellitus (T2DM) to mitigate the risk of cardiovascular diseases (CVD). Data on lipid-control status among patients with T2DM in Bangladesh are scarce. This study was conducted to determine the lipid-control status among patients with T2DM who were on lipid-lowering drugs in the country. Methods: This cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. Adults of both sexes diagnosed with T2DM for at least one year and were on the lipid-lowering drug(s) for a minimum of 3 months were included in the study by consecutive sampling. Patients’ data were collected by face-to-face interviews, and blood samples were collected for fasting lipid profile. The lipid target was set at < 200 mg/dL for total cholesterol (TC), < 150 mg/dL for triglyceride (TG), < 100 mg/dL for low-density lipoprotein cholesterol (LDL-C), > 40 mg/dL for high-density lipoprotein cholesterol (HDL-C), and < 160 mg/dL for non-HDL cholesterol (non-HDL-C). Result: Three thousand sixty patients (age 44.7 ± 13.3 years, female 57%) with T2DM were evaluated. Overall, almost 81% of the study subjects achieved the LDL-C target. Besides, TC, TG, HDL-C, and non-HDL-C targets were achieved by 40.8, 21.6, 66.3, and 44.1% of patients, respectively. However, all the lipid parameters were under control in only 8.8% of patients. Almost 77.6% of the patients with ischemic heart disease, 81.5% of patients with stroke, and 65% of patients with CKD had LDL levels < 70 mg/dL. Only 10.03% achieved the HbA1c target of < 7%. 7.4% of patients achieved both HbA1c < 7% and LDL < 100 mg/dL and 5% achieved both HbA1c < 7% and LDL < 70 mg/dL. Advanced age (aOR 0.97, 95% CI 0.96, 0.98, p < 0.001), longstanding T2DM (aOR 0.53, 95% CI 0.39, 0.72, p < 0.001), and non-statin therapy (aOR 0.25, 95% CI 0.16, 0.37, p < 0.001) were negatively associated with lipid control (LDL < 100 mg/dL) while using oral hypoglycemic drugs or insulin (aOR 2.01, 95% CI 1.45, 2.77, p < 0.001) and having cardiovascular comorbidity (aOR 3.92, 95% CI 3.00, 5.12, p < 0.001) were positively associated with lipid control. Conclusion: Though most patients with T2DM achieved their target LDL level, the prevalence of both glycemic and overall lipid control was low in our study despite lipid-lowering therapy.
- 5 December 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-9
Open AccessStatus of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study
Background: Achievement of lipid targets is crucial in patients with type 2 diabetes mellitus (T2DM) to mitigate the risk of cardiovascular diseases (CVD). Data on lipid-control status among patients with T2DM in Bangladesh are scarce. This study was conducted to determine the lipid-control status among patients with T2DM who were on lipid-lowering drugs in the country. Methods: This cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. Adults of both sexes diagnosed with T2DM for at least one year and were on the lipid-lowering drug(s) for a minimum of 3 months were included in the study by consecutive sampling. Patients’ data were collected by face-to-face interviews, and blood samples were collected for fasting lipid profile. The lipid target was set at < 200 mg/dL for total cholesterol (TC), < 150 mg/dL for triglyceride (TG), < 100 mg/dL for low-density lipoprotein cholesterol (LDL-C), > 40 mg/dL for high-density lipoprotein cholesterol (HDL-C), and < 160 mg/dL for non-HDL cholesterol (non-HDL-C). Result: Three thousand sixty patients (age 44.7 ± 13.3 years, female 57%) with T2DM were evaluated. Overall, almost 81% of the study subjects achieved the LDL-C target. Besides, TC, TG, HDL-C, and non-HDL-C targets were achieved by 40.8, 21.6, 66.3, and 44.1% of patients, respectively. However, all the lipid parameters were under control in only 8.8% of patients. Almost 77.6% of the patients with ischemic heart disease, 81.5% of patients with stroke, and 65% of patients with CKD had LDL levels < 70 mg/dL. Only 10.03% achieved the HbA1c target of < 7%. 7.4% of patients achieved both HbA1c < 7% and LDL < 100 mg/dL and 5% achieved both HbA1c < 7% and LDL < 70 mg/dL. Advanced age (aOR 0.97, 95% CI 0.96, 0.98, p < 0.001), longstanding T2DM (aOR 0.53, 95% CI 0.39, 0.72, p < 0.001), and non-statin therapy (aOR 0.25, 95% CI 0.16, 0.37, p < 0.001) were negatively associated with lipid control (LDL < 100 mg/dL) while using oral hypoglycemic drugs or insulin (aOR 2.01, 95% CI 1.45, 2.77, p < 0.001) and having cardiovascular comorbidity (aOR 3.92, 95% CI 3.00, 5.12, p < 0.001) were positively associated with lipid control. Conclusion: Though most patients with T2DM achieved their target LDL level, the prevalence of both glycemic and overall lipid control was low in our study despite lipid-lowering therapy.
- Open Access
- 26 June 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-9
Comparison of fasting and random lipid profiles among subjects with type 2 diabetes mellitus: an outpatient-based cross-sectional study in Bangladesh
Background: Despite the wide acceptability of fasting lipid profiles in practice, emerging evidence suggests that random lipid profiles might be a convenient alternative for lipid measurement. The objective of the present study was to compare the fasting and random lipid profile among subjects with type 2 diabetes mellitus (T2DM). Methods: The present cross-sectional study included 1543 subjects with T2DM visiting several endocrinology outpatient clinics throughout Bangladesh from January to December 2021. The fasting lipid profile was measured in the morning following 8–10 h of overnight fasting, and the random lipid profile was measured at any time of the day, irrespective of the last meal. The values of fasting and random lipids were compared using the Wilcoxon signed-rank test and Spearman rank correlation coefficients. Results: In this study, a good level of correlation was observed between fasting and random lipid levels [r = 0.793, p < 0.001 for triglyceride (TG); r = 0.873, p < 0.001 for low-density lipoprotein cholesterol (LDL-C); r = 0.609, p < 0.001 for high-density lipoprotein cholesterol (HDL-C); and r = 0.780, p < 0.001 for total cholesterol (TC)]. In addition, TG and TC levels increased by 14% and 0.51%, respectively, in the random state compared to the fasting state (p- <0.05), while LDL-C levels decreased by 0.71% (p-value 0.42). No change was noticed in the HDL-C level. The difference between fasting and random lipid profiles was similar irrespective of patients’ age, sex, BMI, glucose-lowering drug(s), and lipid-lowering therapy. Conclusions: Random lipid profile correlates significantly with fasting lipid profile with little difference. Hence, it might be a reliable alternative for fasting lipid profile in patients with T2DM.
- 26 June 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-9
Open AccessComparison of fasting and random lipid profiles among subjects with type 2 diabetes mellitus: an outpatient-based cross-sectional study in Bangladesh
Background: Despite the wide acceptability of fasting lipid profiles in practice, emerging evidence suggests that random lipid profiles might be a convenient alternative for lipid measurement. The objective of the present study was to compare the fasting and random lipid profile among subjects with type 2 diabetes mellitus (T2DM). Methods: The present cross-sectional study included 1543 subjects with T2DM visiting several endocrinology outpatient clinics throughout Bangladesh from January to December 2021. The fasting lipid profile was measured in the morning following 8–10 h of overnight fasting, and the random lipid profile was measured at any time of the day, irrespective of the last meal. The values of fasting and random lipids were compared using the Wilcoxon signed-rank test and Spearman rank correlation coefficients. Results: In this study, a good level of correlation was observed between fasting and random lipid levels [r = 0.793, p < 0.001 for triglyceride (TG); r = 0.873, p < 0.001 for low-density lipoprotein cholesterol (LDL-C); r = 0.609, p < 0.001 for high-density lipoprotein cholesterol (HDL-C); and r = 0.780, p < 0.001 for total cholesterol (TC)]. In addition, TG and TC levels increased by 14% and 0.51%, respectively, in the random state compared to the fasting state (p- <0.05), while LDL-C levels decreased by 0.71% (p-value 0.42). No change was noticed in the HDL-C level. The difference between fasting and random lipid profiles was similar irrespective of patients’ age, sex, BMI, glucose-lowering drug(s), and lipid-lowering therapy. Conclusions: Random lipid profile correlates significantly with fasting lipid profile with little difference. Hence, it might be a reliable alternative for fasting lipid profile in patients with T2DM.
- Open Access
- 4 January 2023
- Published by Bangladesh Academy of Sciences in TAJ: Journal of Teachers Association
- Vol. 35 (2) , 143-149
Clinical Evaluation of Predisposing Factors of Hypoglycaemia in Diabetic Patients
Background: Hypoglycemia is a common medical problem in diabetic patients, and the potential range of morbidity and mortality in diabetic patients exposed to hypoglycemia is significant. The study was conducted to evaluate the predisposing factors of hypoglycemia in diabetic populations. Methods: This is a descriptive cross-sectional study carried out in the indoor and outdoor patient department of BIRDEM hospital, Dhaka, Bangladesh, from July 2009 to December 2009 after ethical approval in conformity with the revised 1964 Helsinki declaration. Following informed written consent, a total of 50 diabetic patients having hypoglycemia were finally included. Data analysis was done using SPSS 17. Results: In the study population, significant members of hypoglycemic episodes were found in middle age (31-70) insulin-treated patients and poor diabetic education and in those who had other concomitant diseases. Poor dietary compliance (Reduced meal intake in 50% of cases and missed meal in 34% of cases) and lack of proper diabetic education about early recognition and treatment of hypoglycemia also appeared as important contributory factors. Noncompliance with regular exercise (40%) and unaccustomed exercise (4%) contribute to hypoglycemia. A significant number of hypoglycemic patients have chronic renal insufficiency (68%). Conclusion: Hypoglycemia is common in the diabetic population who have poor knowledge and practice about diet, drug exercise technique of, use of insulin devices, and have an underlying systemic illness. So more rational education system and appropriate management of systemic diseases regarding the prevention and treatment of hypoglycemia is demanded by our diabetic patients. TAJ 2022; 35: No-2: 143-149
- 4 January 2023
- Published by Bangladesh Academy of Sciences in TAJ: Journal of Teachers Association
- Vol. 35 (2) , 143-149
Open AccessClinical Evaluation of Predisposing Factors of Hypoglycaemia in Diabetic Patients
Background: Hypoglycemia is a common medical problem in diabetic patients, and the potential range of morbidity and mortality in diabetic patients exposed to hypoglycemia is significant. The study was conducted to evaluate the predisposing factors of hypoglycemia in diabetic populations. Methods: This is a descriptive cross-sectional study carried out in the indoor and outdoor patient department of BIRDEM hospital, Dhaka, Bangladesh, from July 2009 to December 2009 after ethical approval in conformity with the revised 1964 Helsinki declaration. Following informed written consent, a total of 50 diabetic patients having hypoglycemia were finally included. Data analysis was done using SPSS 17. Results: In the study population, significant members of hypoglycemic episodes were found in middle age (31-70) insulin-treated patients and poor diabetic education and in those who had other concomitant diseases. Poor dietary compliance (Reduced meal intake in 50% of cases and missed meal in 34% of cases) and lack of proper diabetic education about early recognition and treatment of hypoglycemia also appeared as important contributory factors. Noncompliance with regular exercise (40%) and unaccustomed exercise (4%) contribute to hypoglycemia. A significant number of hypoglycemic patients have chronic renal insufficiency (68%). Conclusion: Hypoglycemia is common in the diabetic population who have poor knowledge and practice about diet, drug exercise technique of, use of insulin devices, and have an underlying systemic illness. So more rational education system and appropriate management of systemic diseases regarding the prevention and treatment of hypoglycemia is demanded by our diabetic patients. TAJ 2022; 35: No-2: 143-149